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AbstrAct
Background Emergency contraception (EC) was 
approved in the UK as a pharmacy medicine for 
purchase without prescription in 2001. Twenty 
years later we conducted a study to characterise 
routine practice pharmacy provision of EC.
Study design Mystery shopper study of 30 
pharmacies in Edinburgh, Dundee and London 
participating in a clinical trial of contraception 
after EC.
Methods Mystery shoppers, aged ≥16 years, 
followed a standard scenario requesting EC. 
After the pharmacy visit, they completed 
a proforma recording the duration of the 
consultation, where it took place, and whether 
advice was given to them about the importance 
of ongoing contraception after EC.
Results Fifty- five mystery shopper visits were 
conducted. The median reported duration of the 
consultation with the pharmacist was 6 (range 
1–18) min. Consultations took place in a private 
room in 34 cases (62%) and at the shop counter 
in the remainder. In 27 cases (49%) women 
received advice about ongoing contraception. 
Eleven women (20%) left the pharmacy without 
EC due to lack of supplies or of a trained 
pharmacist. Most women were generally positive 
about the consultation.
Conclusions While availability of EC from UK 
pharmacies has undoubtedly improved access, 
the necessity to have a consultation, however 
helpful, with a pharmacist introduces delays 
and around one in five of our mystery shoppers 
left without getting EC. Consultations in private 
are not always possible and little advice is given 
about ongoing contraception. It is time to make 
EC available without a pharmacy consultation.
IntroductIon
It is more than 20 years since emergency 
contraception (EC) was approved in the 
UK as a pharmacy medicine for purchase 
without a doctor’s prescription. Following 
de- regulation, a shift to over- the- counter 
access occurred quite rapidly,1 despite 
EC being available free of charge from 
general practitioners (GPs) and family 
planning clinics but at a cost of around 
£25 in pharmacies. That shift continued 
with time. While 27% of women obtained 
their EC from community pharmacies in 
2003–2004 in Great Britain, by 2007–
2008 the figure had risen to 51%.2 3 In 
late 2008, levonorgestrel EC (LNG- EC, 
Levonelle 1500, Schering Health, UK) was 
made available free of charge without a 
prescription from pharmacies for women 
aged 13 years and older throughout Scot-
land,4 and Wales followed suit in 2011.5 
In England, local arrangements allow EC 
free of charge from pharmacies who agree 
to participate in the scheme but only for 
certain age groups. In most pharmacies 
EC is provided through a ‘patient group 
direction’, a locally agreed proforma 
which lists eligibility criteria for the 
Key messages
 ► Although availability of emergency 
contraception (EC) from pharmacies 
improves access, women in the UK 
still require a consultation with a 
pharmacist.
 ► One in five women may not get EC at 
the first visit to the pharmacy and advice 
about ongoing contraception is not 
always provided.
 ► Opportunities to prevent unintended 
pregnancy are being missed. It is time 
to make EC available as a general sales 
medicine.
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medicine. Although current figures are not available, 
it seems likely that most women now obtain EC from 
pharmacies rather than from a GP or a sexual and 
reproductive health (SRH) service, and many pharma-
cies in England and Wales now offer an online service 
with ‘click and collect’ options or even home delivery 
of supplies.
In 2007 we undertook a mystery shopper study4 to 
evaluate the quality of service provision in community 
pharmacies in Edinburgh, Scotland and to determine 
what advice was being given about contraception after 
EC use. The quality of consultations was generally 
good; over 75% of women were asked appropriate 
questions about eligibility, and over 90% received 
appropriate advice about how to use EC, but fewer 
than half the women received any advice about subse-
quent contraceptives. In 2018–2019 the opportunity 
arose to repeat the mystery shopper study in prepa-
ration for a pragmatic cluster randomised controlled 
trial (‘Bridge- It’ study6) conducted in community 
pharmacies in which women were offered a supply of 
ongoing hormonal contraception when they presented 
for EC, if the pharmacy was in the intervention arm 
of the study. The mystery shopper visits were designed 
to characterise ‘standard care’ in the control arm of 
the study, that is, the routine practice in participating 
pharmacies in managing requests for EC. In 2018–
2019, our interest focused once again on advice about 
ongoing contraception after EC but also generated 
data on how easy (or difficult) it is to access EC in 
pharmacies.
Methods
The study was undertaken in three UK cities (Edin-
burgh, Dundee and London) see6 for details. In the 
control arm of the ‘Bridge -it’ study LNG- EC was 
provided according to the pharmacies’ normal practice 
and women were advised to see their usual contracep-
tive provider for ongoing contraception. Pharmacies 
were trained in the conduct of the study, with training 
focused on provision of the progestogen- only pill 
not the EC. They were told that one or two mystery 
shopper visits would take place before the control arm 
of the study started, but were not told when the visits 
would happen. Visits took place between April 2018 
and January 2019. Mystery shoppers were female 
volunteers aged 16 years and older who received £20 
for each completed visit. Research nurses instructed 
them on the aims of the study, the scenario to be 
followed and the data to be collected. Mystery shop-
pers were advised that they should not swallow the 
EC tablet, but if pressured to do so by the pharmacist, 
then they should admit to being a mystery shopper. 
A simple scenario relating to request for EC (one 
episode of unprotected sex within the last 72 hours) 
was adapted from that used in the earlier study.4 
Both the clinical scenario used (online supplementary 
table 1) and the age of the shoppers were deliberately 
chosen so that none were ineligible to use EC. Immedi-
ately after leaving the pharmacy, the mystery shopper 
completed a data collection proforma, recording the 
time of entering and leaving the store, the duration of 
the consultation and where it took place. The shopper 
also noted whether the pharmacist checked that they 
were eligible for EC and whether the information 
provided included specified topics such as advice on 
continuing contraception. These topics were included 
in the proforma as they constituted recommendations 
for the provision of EC in the national guidelines of 
the Faculty of Sexual and Reproductive Healthcare 
(FSRH).7 Mainly comprising tick box answers, the 
proforma included space for brief free- text comments 
relating to the experience of obtaining EC. Mystery 
shoppers were not given specific instructions on 
requesting privacy. Data from the proforma were 
entered into an Excel database. Two of the investi-
gators (AG and SC) independently grouped the free- 
text comments of the mystery shoppers into common 
themes.
Patient and public involvement
Members of the patient and public involvement (PPI) 
group for the study assisted in identifying suitable 
mystery shoppers, and the scenario to be used as their 
request for EC. The PPI group are involved in the 
dissemination of the study results.
Ethics approval was received from South East Scot-
land REC in June 2017. Approvals were obtained from 
NHS Research Scotland (NRS) and Health Research 
Authority (HRA) England prior to commencement of 
the study.
results
A total of 55 mystery shopper visits (23 in Scotland 
and 32 in London) were conducted at the 30 study 
pharmacies. The mean total time (range) reported 
spent in the pharmacy was 12 (range 1–47) min. The 
median reported duration of the consultation with 
the pharmacist was 6 (range 1–18) min. Six mystery 
shoppers spent over 20 min in the pharmacy while 
five were there for 35 min or longer. Two complained 
about the long wait in the free- text comments. Consul-
tations took place in a private room in 34 cases (62%), 
and the remainder at the counter, although for three 
mystery shoppers the consultation later moved to a 
private room. Not all were given EC and getting it 
was not always straightforward. Eight were told they 
had to swallow the tablet on site. One insisted that 
she wanted to take the EC at home and was asked to 
sign a form documenting this before EC was given; 
another was told that if she paid for EC she could take 
it away, but if she chose the free medicine it had to 
be taken on site. Four mystery shoppers were told EC 
was not in stock, two were 16 years old and visited the 
same pharmacy on the same afternoon, both were told 
that they should return 90 min later. Seven mystery 
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Box 1 Free- text comments from mystery shoppers
Overall impression of the consultation
“Felt comfortable talking to this pharmacist, non- 
judgemental approach. Happy not to be ‘grilled'. Asked 
good questions about if was non consensual. Also advised 
about STI testing.” [Mystery shopper 18]
“Consulted by a very lovely informative pharmacist 
who covered all the basics in terms of advice given to 
me - even discussed upcoming research studies in EC. 
Pleasant experience to what can easily be an awkward 
conversation.” [Mystery shopper 17]
“Very rushed, pharmacist made it clear he didn’t 
understand what information he had to ask/explain. 
Pharmacist had the form in front of him but did not read 
from it just asked questions regarding allergies etc. and 
wrote at the bottom of the form.” [Mystery shopper 26]
Told to take emergency contraception (EC) on the 
premises
“… she was also insistent that I took the medication in 
the pharmacy but I declined explaining that I need to 
take medication with food so she made me sign to say 
that I had refused to take the medication in front of her.” 
[Mystery shopper 16]
“… he did however request for me to take the pill in 
front of him to make sure it is for me and not someone 
else. He said this is required legally. I then stated 
that I am uncomfortable with it, apologised for any 
inconvenience and left the pharmacy.” [Mystery shopper 
49]
EC unavailable at time of presentation
“There was only a pharmacist on duty but she was not 
able to dispense the emergency contraception pill as she 
was not qualified. The person that usually does it was not 
in that day.” [Mystery shopper 53]
“The first pharmacist at the counter did not know if 
they are supplying EC so she called another one, who 
just asked whether I am registered at a GP and whether 
I have ID with me (she asked this all quite rudely!). She 
then gave me the form to complete and repeatedly asked 
from my ID and other details, which I was not comfortable 
with, so left.” [Mystery shopper 58]
Concerns about privacy
“Initially asked at counter and the female said to wait for 
the pharmacist. Had to repeat to pharmacist that I needed 
EC. Quite a few people around.” [Mystery shopper 55]
shoppers were told that no trained pharmacist was 
available to provide EC, and two were persuaded 
that a copper intrauterine device (Cu- IUD) would 
be more effective and were directed to a local SRH 
clinic – neither was offered EC as an interim measure. 
One was told that she had to be registered with a GP 
to get free EC. In most cases where EC could not be 
provided an alternative pharmacy was recommended. 
Most pharmacies (London sites) not participating in 
the English scheme allowing EC to be provided free of 
charge recommended other pharmacies where it was 
available free. In all, 11 mystery shoppers (20%) were 
unable to get EC from the pharmacy they visited when 
they first presented; a further two were advised to 
attend elsewhere for a Cu- IUD insertion. In London, 
seven shoppers were told that the pharmacy could not 
offer free supplies, and three were offered free EC but 
only if they provided proof of identity and age.
Forty- eight shoppers wrote brief free- text comments 
about their experience in the pharmacy. The four most 
common themes (box 1) were the overall impression 
of the consultation; being told to take the EC on the 
premises; EC unavailable at the time of presentation; 
and concerns about privacy. Eighteen mystery shop-
pers commented very positively about the manner of 
the pharmacists. Positive comments about the consulta-
tions included: very informative, lovely manner, non- 
judgemental and understanding, very approachable, 
friendly, calm and reassuring. Only six mystery shop-
pers were at all negative. Of these, two complained that 
they felt the consultation was rushed, two complained 
about a long wait to be seen, and two mentioned the 
consultation being overheard by others.
Table 1 shows the results for relevant information 
provided or elicited by pharmacist. Only 27 mystery 
shoppers (49%) received advice (verbal or written) 
about contraception after EC.
dIscussIon
This mystery shopper study suggests that getting EC 
from UK pharmacies is often not easy. A significant 
proportion of shoppers left without EC. Although some 
were told to return later and others were directed to a 
different pharmacy or to a clinic, it is possible that in 
real life many women would have given up the quest. 
Even if they did eventually manage to get a supply, the 
sooner after intercourse EC is taken the more likely it is 
to be effective, so delays jeopardise successful preven-
tion of pregnancy. While it is heartening to learn that 
some pharmacists encouraged Cu- IUD insertion for 
EC, the mystery shoppers received verbal advice about 
contraception after EC in just under half of the visits, 
which is similar to the findings of a 2017 study.4 The 
study also demonstrated that privacy for the consulta-
tion is not guaranteed and that pharmacies sometimes 
request proof of identity or ingestion of EC on the 
premises, which are not recognised requirements in 
the UK.
The main limitation of this study is its size, with 
just 55 visits to 30 pharmacies in three different cities, 
and the fact that it did not involve a random sample 
of pharmacies (unlike our earlier study4) and so the 
findings may well not be representative. However, 
since all participating pharmacies had agreed to take 
part in, and had recently undergone training for, 
the Bridge- it study6 it is not unreasonable to assume 
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Table 1 Topics discussed at the 55 mystery shopper visits for 
emergency contraception
Topic Yes No Blank
Reason for needing, or eligibility for, 
emergency contraception
43 12
Verbal information/advice about importance of 
contraception after emergency contraception
27 27 1
Written information/advice about 
importance of contraception after emergency 
contraception
5 50
Verbal information about local sexual and 
reproductive health clinic/general practice for 
contraception
30 25
Verbal Information/advice about conducting a 
pregnancy test in 3 weeks
22 32 1
Written information/advice about conducting 
a pregnancy test in 3 weeks
2 53
Blank indicates not completed.
that the performance of these pharmacies, sensitised 
to the EC consultation, would likely be better than 
average. Other mystery shopper studies from the UK 
have shown a similar, or worse, picture. The British 
Pregnancy Advisory Service (BPAS) undertaking a 
similar study in 30 pharmacies in England8 reported 
that while the pharmacists provided a kind and non- 
judgemental service, the consultation was considered 
‘unprofessional’ in around 10% of visits (eg, the phar-
macist demanding to see a negative pregnancy test 
before providing EC), and in 7% of cases the shopper 
was turned away without further help or told to come 
back later. BPAS concluded that in nearly one in five 
visits the woman would have missed the opportunity 
to prevent an unwanted pregnancy.8
Mystery shopper studies relating to EC access from 
pharmacies have also been published from other 
countries such as Australia and the USA.9–13 While 
the research question posed by each investigator was 
somewhat different to that of our mystery shopper 
study, all concluded that pharmacists’ practices are 
variable and not always in line with the recommenda-
tions in guidelines.
According to the Medicines and Healthcare products 
Regulatory Agency (MHRA), the underlying principle 
for classifying medicines in the UK is to “maximise 
timely access to effective medicines while minimising 
the risk of harm from inappropriate use”.14 In the case 
of EC, timely access is critical since the efficacy of both 
oral EC products available in the UK declines with time 
following unprotected sexual intercourse.15 Pharmacy- 
only medicines can be bought, but only from phar-
macies, and require the presence of a pharmacist, an 
arrangement which the MHRA considers as conferring 
“an intermediate level of control”.14 Pharmacy- only 
medicines are not usually displayed on open shelves 
but rather are kept ‘behind the counter’, which means 
that women need to ask for them at the counter and 
this may put many women off trying to access EC.
The Royal Pharmaceutical Society16 argues that the 
mandatory consultation provides an important oppor-
tunity to ensure women are taking the EC within the 
correct time frame, to discuss other methods of contra-
ception and other sexual and reproductive health 
issues such as sexually transmitted infection testing, 
and to address any safeguarding concerns. In our study 
only half of the pharmacists raised the issue of ongoing 
contraception. This is perhaps unsurprising, given phar-
macies are often extremely busy and people attending 
a pharmacy expect a rapid service. The median time 
spent with the pharmacists by our mystery shoppers 
was 6 min, slightly less than the average duration of 
a consultation in general practice. However, even this 
may be unnecessary. The instruction for use of EC is 
simple, and most women in the UK present for EC 
well within the 72 hours time window.17 There are 
no absolute contraindications to the use of either of 
the currently available methods of oral EC.7 The UK 
FSRH clearly recommends that any small theoretical 
risk of inappropriate use is far outweighed by the risks 
associated with pregnancy.7
No mystery shopper study has evaluated consulta-
tions for EC within general practices or SRH clinics; 
and of course even with a prescription from a doctor, 
women may encounter similar barriers in terms of 
waiting times, lack of stock and of a trained pharmacist 
to fill the prescription. Although generally helpful and 
sympathetic, pharmacists fulfilling this “intermediate 
level of control” actually act as gatekeepers and, while 
they offer longer and much less restricted opening 
hours, this study and the BPAS study8 demonstrate 
that they are often unable to “maximise timely access”. 
Our study and that of BPAS suggest that providing EC 
as a pharmacy medicine with the mandatory need to 
have a consultation with a pharmacist could result in a 
missed opportunity to prevent unintended pregnancy 
in at least 20% of attendances. The lack of provision 
of advice on ongoing contraception from the phar-
macies in this study, or indeed the opportunity to be 
prescribed ongoing contraception by an independent 
prescriber pharmacist, is a wasted opportunity to 
improve the sexual health of women who preferen-
tially access healthcare at their community pharmacy
Timely access to EC prevents pregnancy for many 
individual women who take it.15 In their review of the 
effects of making EC available free of charge in Wales, 
Mantzourani and colleagues concluded that access to 
free EC in pharmacies had contributed to reducing 
teenage conceptions.5 Black and colleagues18 analysed 
data from the second and third British National Surveys 
of Sexual Attitudes and Lifestyles undertaken in 1999–
2001 and in 2010–2012, respectively. They reported 
increased use among single women, women living in 
less affluent areas and among women obtaining EC 
from pharmacies rather than other healthcare settings. 
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The increased use was seen among women with some 
but not all risk factors for unintended pregnancy – 
women using less effective methods of contraception 
(a sizeable increase) and those with two or more sexual 
partners in the last year.
When EC was first approved as a pharmacy medicine 
in the UK it was predicted that women would abandon 
more effective methods of contraception, have more 
risky sex and that abortion rates would soar.19 Over 
the first 10 years after EC became available without 
prescription there was only a small rise in use in Britain 
from 2.3% to 3.6% of women having used EC in the 
last year.18 If more women with risk factors for unin-
tended pregnancy are taking EC then perhaps phar-
macy access is having a small public health benefit; 
however, the benefit could be much greater if EC was 
available on the General Sales List (GSL) and purchas-
able from a range of outlets. According to the MHRA, 
GSL is appropriate for medicines which can, with 
reasonable safety, be sold or supplied otherwise than 
by or under the supervision of a pharmacist. The term 
‘with reasonable safety’ has been defined as “‘where 
the hazard to health, the risk of misuse, or the need to 
take special precautions in handling is small and where 
wider sale would be a convenience to the purchaser”. 
While this mystery shopper study was undertaken in 
the context of providing LNG- EC, the need for EC, 
the practicalities of using it and the desirability of 
providing information about ongoing contraception 
are no different for the other oral EC available in the 
UK (ulipristal acetate, ellaOne, HRA Pharma) and we 
strongly suggest that both methods of EC should be 
available as GSL medicines.
Twenty years after EC was first approved as a phar-
macy medicine in the UK it seems that there is more 
than enough evidence to demonstrate that it does not 
present a hazard to health, is not widely misused, does 
not need special precautions, and that more opportu-
nities to obtain EC would very clearly be of benefit to 
women and possibly to public health.
conclusIons
While availability of EC from UK pharmacies has 
undoubtedly improved access, the necessity to have 
a consultation with a pharmacist introduces delays, 
and around one in five of our mystery shoppers left 
without getting EC. It is time to make EC available 
without a pharmacy consultation.
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